Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

Open access
Agarwal, Arnav, Basmaji, John, Muttalib, Fiona, Granton, David, Chaudhuri, Dipayan, Chetan, Devin, Hu, Malini, Fernando, Shannon M., Honarmand, Kimia, Bakaa, Layla, Brar, Sonia, Rochwerg, Bram, Adhikari, Neill K., Lamontagne, Francois, Murthy, Srinivas, Hui, David S. C., Gomersall, Charles, Mubareka, Samira, Diaz, Janet V., Burns, Karen E. A., Couban, Rachel, Ibrahim, Quazi, Guyatt, Gordon H., Vandvik, Per O. · 2020 · Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Abstract

Purpose We conducted two World Health Organization-commissioned reviews to inform use of high-flow nasal cannula (HFNC) in patients with coronavirus disease (COVID-19). We synthesized the evidence regarding efficacy and safety (review 1), as well as risks of droplet dispersion, aerosol generation, and associated transmission (review 2) of viral products. Source Literature searches were performed in Ovid MEDLINE, Embase, Web of Science, Chinese databases, and medRxiv. Review 1 : we synthesized results from randomized-controlled trials (RCTs) comparing HFNC to conventional oxygen therapy (COT) in critically ill patients with acute hypoxemic respiratory failure. Review 2: we narratively summarized findings from studies evaluating droplet dispersion, aerosol generation, or infection transmission associated with HFNC. For both reviews, paired reviewers independently conducted screening, data extraction, and risk of bias assessment. We evaluated certainty of evidence using GRADE methodology. Principal findings No eligible studies included COVID-19 patients. Review 1: 12 RCTs ( n = 1,989 patients) provided low-certainty evidence that HFNC may reduce invasive ventilation (relative risk [RR], 0.85; 95% confidence interval [CI], 0.74 to 0.99) and escalation of oxygen therapy (RR, 0.71; 95% CI, 0.51 to 0.98) in patients with respiratory failure. Results provided no support for differences in mortality (moderate certainty), or in-hospital or intensive care length of stay (moderate and low certainty, respectively). Review 2 : four studies evaluating droplet dispersion and three evaluating aerosol generation and dispersion provided very low certainty evidence. Two simulation studies and a crossover study showed mixed findings regarding the effect of HFNC on droplet dispersion. Although two simulation studies reported no associated increase in aerosol dispersion, one reported that higher flow rates were associated with increased regions of aerosol density. Conclusions High-flow nasal cannula may reduce the need for invasive ventilation and escalation of therapy compared with COT in COVID-19 patients with acute hypoxemic respiratory failure. This benefit must be balanced against the unknown risk of airborne transmission. Objectif Nous avons réalisé deux comptes rendus sur commande de l’Organisation mondiale de la santé pour guider l’utilisation de canules nasales à haut débit (CNHD) chez les patients ayant contracté le coronavirus (COVID-19). Nous avons synthétisé les données probantes concernant leur efficacité et leur innocuité (compte rendu 1), ainsi que les risques de dispersion des gouttelettes, de génération d’aérosols, et de transmission associée d’éléments viraux (compte rendu 2). Source Des recherches de littérature ont été réalisées dans les bases de données Ovid MEDLINE, Embase, Web of Science, ainsi que dans les bases de données chinoises et medRxiv. Compte rendu 1 : nous avons synthétisé les résultats d’études randomisées contrôlées (ERC) comparant les CNHD à une oxygénothérapie conventionnelle chez des patients en état critique atteints d’insuffisance respiratoire hypoxémique aiguë. Compte rendu 2 : nous avons résumé sous forme narrative les constatations d’études évaluant la dispersion de gouttelettes, la génération d’aérosols ou la transmission infectieuse associées aux CNHD. Pour les deux comptes rendus, des réviseurs appariés ont réalisé la sélection des études, l’extraction des données et l’évaluation du risque de biais de manière indépendante. Nous avons évalué la certitude des données probantes en nous fondant sur la méthodologie GRADE. Constatations principales Aucune étude éligible n’incluait de patients atteints de COVID-19. Compte rendu 1 : 12 ERC ( n = 1989 patients) ont fourni des données probantes de certitude faible selon lesquelles les CNHD réduiraient la ventilation invasive (risque relatif [RR], 0,85; intervalle de confiance [IC] 95 %, 0,74 à 0,99) et l’intensification de l’oxygénothérapie (RR, 0,71; IC 95 %, 0,51 à 0,98) chez les patients atteints d’insuffisance respiratoire. Les résultats n’ont pas démontré de différences en matière de mortalité (certitude modérée), ni de durée du séjour hospitalier ou à l’unité des soins intensifs (certitude modérée et faible, respectivement). Compte rendu 2 : quatre études évaluant la dispersion de gouttelettes et trois évaluant la génération et la dispersion d’aérosols ont fourni des données probantes de très faible certitude. Deux études de simulation et une étude croisée ont donné des résultats mitigés quant à l’effet des CNHD sur la dispersion des gouttelettes. Bien que deux études de simulation n’aient rapporté aucune augmentation associée concernant la dispersion d’aérosols, l’une a rapporté que des taux de débit plus élevés étaient associés à des régions à densité d’aérosols élevée plus grandes. Conclusion Les canules nasales à haut débit pourraient réduire la nécessité de recourir à la ventilation invasive et l’escalade des traitements par rapport à l’oxygénothérapie conventionnelle chez les patients atteints de COVID-19 souffrant d’insuffisance respiratoire hypoxémique aiguë. Cet avantage doit être soupesé contre le risque inconnu de transmission atmosphérique.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12630-020-01740-2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 195

Metadata

Authors
Agarwal, A., Basmaji, J., Muttalib, F., Granton, D., Chaudhuri, D., Chetan, D., Hu, M., Fernando, S. M., Honarmand, K., Bakaa, L., Brar, S., Rochwerg, B., Adhikari, N. K., Lamontagne, F., Murthy, S., Hui, D. S. C., Gomersall, C., Mubareka, S., Diaz, J. V., Burns, K. E. A., Couban, R., Ibrahim, Q., Guyatt, G. H., & Vandvik, P. O.
Venue
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Published
2020-06-15
Volume
67
Issue
9
Pages
1217-1248
ISSN
  • 0832-610X (ISSN-L)
  • 1496-8975
OpenAlex
W3035761977
Cited by
195
References
10
FWCI
8.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. https://app.cochat.ai/papers/10.1007/s12630-020-01740-2
The paper
Agarwal, A., Basmaji, J., Muttalib, F., Granton, D., Chaudhuri, D., Chetan, D., Hu, M., Fernando, S. M., Honarmand, K., Bakaa, L., Brar, S., Rochwerg, B., Adhikari, N. K., Lamontagne, F., Murthy, S., Hui, D. S. C., Gomersall, C., Mubareka, S., Diaz, J. V., . . . Vandvik, P. O. (2020). High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. https://doi.org/10.1007/s12630-020-01740-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.